Acorda Therapeutics to host analyst and investor breakfast
Acorda Therapeutics, Inc. today announced that it will host an analyst and investor breakfast on April 14, 2007, at the American Academy of Neurology annual meeting.
A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston, along with the Harvard School of Dental Medicine.